CN106660937A - 用于治疗adhd的达斯曲林(dasotraline)剂量和方法 - Google Patents

用于治疗adhd的达斯曲林(dasotraline)剂量和方法 Download PDF

Info

Publication number
CN106660937A
CN106660937A CN201580027353.3A CN201580027353A CN106660937A CN 106660937 A CN106660937 A CN 106660937A CN 201580027353 A CN201580027353 A CN 201580027353A CN 106660937 A CN106660937 A CN 106660937A
Authority
CN
China
Prior art keywords
acid
adhd
dastroline
treatment
methylphenidate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580027353.3A
Other languages
English (en)
Chinese (zh)
Inventor
安东尼·龙贝尔
肯尼思·克波兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of CN106660937A publication Critical patent/CN106660937A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201580027353.3A 2014-05-13 2015-05-12 用于治疗adhd的达斯曲林(dasotraline)剂量和方法 Pending CN106660937A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461992619P 2014-05-13 2014-05-13
US61/992,619 2014-05-13
PCT/US2015/030357 WO2015175523A1 (en) 2014-05-13 2015-05-12 Dosage of dasotraline and method for treatment of adhd

Publications (1)

Publication Number Publication Date
CN106660937A true CN106660937A (zh) 2017-05-10

Family

ID=54480549

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580027353.3A Pending CN106660937A (zh) 2014-05-13 2015-05-12 用于治疗adhd的达斯曲林(dasotraline)剂量和方法

Country Status (10)

Country Link
US (1) US10076503B2 (enExample)
EP (1) EP3143000A4 (enExample)
JP (1) JP2017515849A (enExample)
KR (1) KR20170005088A (enExample)
CN (1) CN106660937A (enExample)
AU (1) AU2015259346A1 (enExample)
CA (1) CA2948839A1 (enExample)
IL (1) IL248847A0 (enExample)
MX (1) MX2016014768A (enExample)
WO (1) WO2015175523A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020092496A1 (en) * 2018-10-31 2020-05-07 Sunovion Pharmaceuticals Inc. Methods of treating central nervous system disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556676A (en) * 1979-11-01 1985-12-03 Pfizer Inc. Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4981870A (en) * 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
WO2004024669A1 (en) * 2002-09-16 2004-03-25 Sepracor, Inc. Treatment of cns disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide
CN102740842A (zh) * 2009-12-04 2012-10-17 桑诺维恩药品公司 反式降舍曲林的制剂、盐和多晶型物及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556676A (en) * 1979-11-01 1985-12-03 Pfizer Inc. Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4981870A (en) * 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
WO2004024669A1 (en) * 2002-09-16 2004-03-25 Sepracor, Inc. Treatment of cns disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide
CN102740842A (zh) * 2009-12-04 2012-10-17 桑诺维恩药品公司 反式降舍曲林的制剂、盐和多晶型物及其应用

Also Published As

Publication number Publication date
JP2017515849A (ja) 2017-06-15
EP3143000A4 (en) 2017-12-13
US10076503B2 (en) 2018-09-18
IL248847A0 (en) 2017-01-31
MX2016014768A (es) 2017-03-06
WO2015175523A1 (en) 2015-11-19
KR20170005088A (ko) 2017-01-11
EP3143000A1 (en) 2017-03-22
CA2948839A1 (en) 2015-11-19
US20170266134A1 (en) 2017-09-21
AU2015259346A1 (en) 2016-12-08

Similar Documents

Publication Publication Date Title
JP2021098743A (ja) 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物
JP4938905B2 (ja) 選択的ｓ１ｐ１レセプターアゴニストの投与法
JP2011511071A5 (enExample)
RU2007140348A (ru) Способы и композиции для лечения заболеваний цнс
EP3678665A1 (en) Combination therapy of lasmiditan and a cgrp antagonist for use in the treatment of migraine
KR20120101456A (ko) 중추 매개의 오심 및 구토를 치료하기 위한 조성물 및 방법
US20110070319A1 (en) Bifeprunox doses for treating schizophrenia
JP2013505983A5 (enExample)
CN107072988A (zh) 包含辛波莫德和拉喹莫德的用于治疗多发性硬化症的组合
TW200831097A (en) Treatment of anxiety with eszopiclone
JP2023181398A (ja) 認知症および神経変性状態における興奮、精神病および認知機能低下のためのシクロベンザプリン処置
Paton Deutetrabenazine: treatment of hyperkinetic aspects of Huntington’s disease, tardive dyskinesia and Tourette syndrome
JP7539898B2 (ja) オピオイド鎮痛耐性を治療するためのｍＧｌｕＲ５アンタゴニストの使用
CN106660936A (zh) 用于治疗adhd的方法和达斯曲林(dasotraline)组合物
CN106660937A (zh) 用于治疗adhd的达斯曲林(dasotraline)剂量和方法
JP2023526634A (ja) 高アンモニア血症を治療するためのオルニチンフェニルアセテートの使用
CN116323604A (zh) 5-甲基-1,2,4-噁二唑-3-基化合物的低剂量方案和制剂
Ryden Efficacy of epanolol versus metoprolol in angina pectoris: report from a Swedish multicentre study of exercise tolerance
US8222278B2 (en) Treatment of attention-deficit/hyperactivity disorder
Schmidt et al. P. 3. c. 046 Efficacy and safety of JNJ 37822681, a fast dissociating D2 receptor antagonist, in the treatment of schizophrenia
KR20240013810A (ko) 간 손상을 갖는 개체에의 화합물의 투여
Tack et al. Su1377 Efficacy of Oral Ibodutant in IBS-D Female Patients Measured by Abdominal Pain Severity-An Iris 2 Post-Hoc Analysis
EP2453885A1 (en) Exo-s-mecamylamine method, use, and compound for treatment

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170510

WD01 Invention patent application deemed withdrawn after publication